Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869736 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2TPSAB1CYP3A4HDAC1HDAC2 | |
| SCHEMBL23869737 | 0.72 | CYP3A4 (0.43) | SMN1; SMN2CYP3A4 | |
| SCHEMBL23869794 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2HDAC1HDAC2HPGDALOX15 | |
| SCHEMBL22821498 | 0.69 | SMN1; SMN2 (0.38) | SMN1; SMN2HDAC1HDAC2 | |
| SCHEMBL23869876 | 0.67 | NPC1 (0.34) | — | |
| SCHEMBL23869786 | 0.65 | HTT (0.39) | SMN1; SMN2CYP3A4HPGDTDP1 | |
| SCHEMBL15244706 | 0.63 | TRPV3 (0.45) | SUCNR1 | |
| SCHEMBL23869735 | 0.62 | HTT (0.38) | SMN1; SMN2HPGDTDP1 | |
| SCHEMBL10634876 | 0.60 | HRH3 (0.53) | CYP3A4HDAC1HDAC2ALOX15 | |
| SCHEMBL23869793 | 0.59 | KDM4A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | SMN1; SMN2 4579/4885TPSAB1 109/4885CYP3A4 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.